Wells Fargo & Company Increases Masimo (NASDAQ:MASI) Price Target to $205.00

Masimo (NASDAQ:MASI) had its price target increased by investment analysts at Wells Fargo & Company from $193.00 to $205.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s target price points to a potential upside of 10.10% from the stock’s current price.

Several other brokerages also recently commented on MASI. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday. Raymond James increased their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Piper Sandler increased their target price on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $194.80.

Masimo Stock Down 2.2 %

Shares of NASDAQ:MASI opened at $186.20 on Wednesday. Masimo has a 52-week low of $101.61 and a 52-week high of $192.62. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm has a market capitalization of $9.97 billion, a P/E ratio of 128.41 and a beta of 1.02. The stock has a 50 day moving average price of $172.95 and a 200-day moving average price of $153.10.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. As a group, equities research analysts anticipate that Masimo will post 4.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Masimo

Institutional investors have recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its stake in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 60 shares during the period. EverSource Wealth Advisors LLC raised its stake in Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 64 shares during the period. Blue Trust Inc. raised its stake in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 71 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Masimo by 0.8% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock worth $1,622,000 after acquiring an additional 82 shares during the period. Finally, Thrivent Financial for Lutherans raised its position in shares of Masimo by 0.8% during the fourth quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock valued at $1,728,000 after buying an additional 83 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.